Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1994 1
1995 2
1997 1
2007 1
2008 2
2010 3
2011 4
2012 6
2013 5
2014 2
2015 5
2016 5
2017 3
2018 3
2019 4
2020 1
2021 7
2022 11
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for S. razavian
Search for S. Razavyan instead (1 results)
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
BACKGROUND: Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A neph …
BACKGROUND: Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly redu …
Generalizable deep learning model for early Alzheimer's disease detection from structural MRIs.
Liu S, Masurkar AV, Rusinek H, Chen J, Zhang B, Zhu W, Fernandez-Granda C, Razavian N. Liu S, et al. Sci Rep. 2022 Oct 17;12(1):17106. doi: 10.1038/s41598-022-20674-x. Sci Rep. 2022. PMID: 36253382 Free PMC article.
Early diagnosis of Alzheimer's disease plays a pivotal role in patient care and clinical trials. ...We validate both models on an internal held-out cohort from The Alzheimer's Disease Neuroimaging Initiative (ADNI) and on an external independent cohort from The Nati …
Early diagnosis of Alzheimer's disease plays a pivotal role in patient care and clinical trials. ...We validate both models on an int …
Antiplatelet agents for chronic kidney disease.
Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Natale P, et al. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4. Cochrane Database Syst Rev. 2022. PMID: 35224730 Free PMC article. Review.
Ethics of Gamification in Health and Fitness-Tracking.
Arora C, Razavian M. Arora C, et al. Int J Environ Res Public Health. 2021 Oct 21;18(21):11052. doi: 10.3390/ijerph182111052. Int J Environ Res Public Health. 2021. PMID: 34769570 Free PMC article.
Helicobacter pylori infection and risk of multiple sclerosis: An updated meta-analysis.
Arjmandi D, Abdollahi A, Ardekani A, Razavian I, Razavian E, Sartip B, Mahjour S, Parsa H, Kyvanani NA, Marhoommirzabak E, Kountouras J, Rostami A. Arjmandi D, et al. Helicobacter. 2022 Dec;27(6):e12927. doi: 10.1111/hel.12927. Epub 2022 Aug 31. Helicobacter. 2022. PMID: 36046943 Review.
CONCLUSIONS: Our findings do not support the hypothesis that H. pylori infection represents a protective factor against the development of MS; however, the results varied depending on the diagnostic method(s). Particularly, a significant positive association was identified …
CONCLUSIONS: Our findings do not support the hypothesis that H. pylori infection represents a protective factor against the development of M …
Antioxidants for chronic kidney disease.
Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T, Webster AC, Perkovic V. Jun M, et al. Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD008176. doi: 10.1002/14651858.CD008176.pub2. Cochrane Database Syst Rev. 2012. PMID: 23076940 Free PMC article. Updated. Review.
OBJECTIVES: To examine the benefits and harms of antioxidant therapy on mortality and cardiovascular events in people with CKD stages 3 to 5; dialysis, and kidney transplantation patients. SEARCH METHODS: We searched the Cochrane Renal Group's specialised register (July 20 …
OBJECTIVES: To examine the benefits and harms of antioxidant therapy on mortality and cardiovascular events in people with CKD stages 3 to 5 …
Antiplatelet agents for chronic kidney disease.
Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, Jardine MJ, Webster AC, Zoungas S, Strippoli GF. Palmer SC, et al. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008834. doi: 10.1002/14651858.CD008834.pub2. Cochrane Database Syst Rev. 2013. PMID: 23450589 Review.
SEARCH METHODS: In January 2011 we searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and the Cochrane Renal Group's Specialised Register without language restriction. SELECTION CRITERIA: We selected randomised controlled trials of any a …
SEARCH METHODS: In January 2011 we searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and the Cochrane R …
72 results